According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
GRFS has been the subject of several other research reports. JPMorgan Chase & Co. downgraded Sogou from a neutral rating to an underweight rating and decreased their price objective for the company from $5.50 to $4.12 in a report on Thursday, June 27th. BidaskClub upgraded Workhorse Group from a hold rating to a buy rating in a report on Monday. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $20.75.
Shares of NASDAQ GRFS traded down $0.04 during midday trading on Tuesday, hitting $22.11. 31,756 shares of the stock traded hands, compared to its average volume of 2,223,324. The company has a market capitalization of $15.09 billion, a P/E ratio of 18.93, a PEG ratio of 1.31 and a beta of 1.16. GRIFOLS S A/S has a one year low of $17.42 and a one year high of $22.50. The company’s 50 day moving average is $20.14. The company has a current ratio of 2.87, a quick ratio of 1.13 and a debt-to-equity ratio of 1.41.
GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.25. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. GRIFOLS S A/S had a return on equity of 15.49% and a net margin of 12.35%. Research analysts predict that GRIFOLS S A/S will post 1.27 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in GRFS. Deutsche Bank AG boosted its position in shares of GRIFOLS S A/S by 670.3% during the fourth quarter. Deutsche Bank AG now owns 12,427,277 shares of the biotechnology company’s stock valued at $228,164,000 after buying an additional 10,813,901 shares during the last quarter. Norges Bank purchased a new position in GRIFOLS S A/S in the fourth quarter worth $57,748,000. JPMorgan Chase & Co. boosted its position in GRIFOLS S A/S by 856.0% in the first quarter. JPMorgan Chase & Co. now owns 1,558,478 shares of the biotechnology company’s stock worth $31,340,000 after purchasing an additional 1,395,461 shares during the last quarter. FIL Ltd boosted its position in GRIFOLS S A/S by 12.2% in the first quarter. FIL Ltd now owns 8,170,942 shares of the biotechnology company’s stock worth $164,318,000 after purchasing an additional 887,474 shares during the last quarter. Finally, Impax Asset Management Group plc boosted its position in GRIFOLS S A/S by 1,557.5% in the fourth quarter. Impax Asset Management Group plc now owns 482,189 shares of the biotechnology company’s stock worth $8,853,000 after purchasing an additional 453,098 shares during the last quarter. 19.01% of the stock is currently owned by institutional investors.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Recommended Story: Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.